Why I Would Buy Big Yellow Group plc, Finsbury Food Group plc And AstraZeneca plc

Royston Wild lays out the investment case for Big Yellow Group plc (LON: BYG), Finsbury Food Group plc (LON: FIF) and AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three Thursday headline makers that stock pickers should seriously consider.

Big Yellow Group

Storage house Big Yellow Group (LSE: BYG) greeted the market with yet another positive update in Thursday business, in turn pushing shares in the business 1.7% higher on the day. The Bagshot business saw like-for-like revenues leap 10% during April-June, to £20.7m, and its underlying occupancy rate jumped to 76.3% from 71.2% during the corresponding 2014 period.

And Big Yellow said that it expects this occupancy rate to leap another three to four percentage points during the current year, a projection I fully expect the firm to realise as Britons’ hoarding culture — boosted by improving spending power — fuels the need for extra space. This view is shared by the City, and earnings growth of 12% and 13% are pencilled in for the years concluding March 2016 and 2017 correspondingly.

Although Big Yellow sports slightly-elevated P/E ratios of 21.5 times and 19.2 times for these years, I expect these to continue collapsing in line with strong demand. And in my opinion projected dividends of 24.5p per share for 2016 and 27.6p for 2017 more than offsets these multiples, creating chunky yields of 3.8% and 4.2%.

Finsbury Food Group

Like Big Yellow, Finsbury Food Group (LSE: FIF) also cheered investors with a bubbly trading update during today’s session and was consequently dealing 6.3% higher. The stock has gained 54% since the turn of the year, propelling the business to current record highs of 92.5p per share at the current time. But I reckon further hefty gains can be expected.

Finsbury Foods announced that total sales jumped 45.8% during the 12 months concluding June 2015, helped by the recent acquisition of Fletchers. Consequently the specialty baker said it expects to exceed current profit expectations. So current City forecasts of a 10% earnings decline for the year could be set for a significant upgrade given today’s release, while predictions of a 27% increase in the current period could also receive a shot in the arm.

I believe that Finsbury Foods offers brilliant value for money, the caterer boasting an ultra-cheap earnings multiple of 9.8 for 2016 — any reading below 10 times is widely considered too good to pass on. When you factor in a projected dividend of 2.8p per share, too, producing a meaty 3.4% yield, I believe the food manufacturer is a hugely appetising stock pick.

AstraZeneca

Unlike its FTSE compatriots, however, AstraZeneca (LSE: AZN) was recently dealing 0.4% lower in Thursday’s session and this extends the broad downtrend seen during the past few months. However, I believe this current weakness — AstraZeneca has shed 11% since the middle of April — makes the business a bargain at the current time, even though the problem of exclusivity losses looks set to continue.

The number crunchers expect the London firm to arrest the heavy earnings declines of recent years in 2015 with a bottom-line stagnation, although a fresh 3% fall is predicted for 2016. But I am convinced AstraZeneca’s reinvigorated R&D pipeline — combined with surging healthcare demand from emerging regions — makes the business a terrific long-term growth pick. The business received FDA approval for its Iressa lung cancer drug just this week, and AstraZeneca plans to release a further six oncology-related products during the next five years alone.

I consider a prospective P/E multiple of 15.5 times decent value given these hot product prospects, while juicy dividend projections around 285 US cents for 2015 and 2016 cement the investment case in my opinion — these forecasts create a produce market-beating yield of 4.3%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

What are Rolls-Royce shares really worth?

Our writer thinks Rolls-Royce shares might be undervalued even after a staggering price increase. But he also sees reasons to…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

This FTSE 250 company just released impressive results, overshadowed by a dire political situation

Our writer takes a look into an under-the-radar FTSE 250 stock that may have a lot of potential if it…

Read more »

Investing Articles

The Dowlais share price is SURGING after Q3 earnings. I think the FTSE 250 stock still looks like a bargain

One of the worst-performing FTSE 250 stocks of 2024 is up 17% after its Q3 trading update. But Stephen Wright…

Read more »

Investing For Beginners

2 UK shares that insiders have been buying this month

Jon Smith reviews two purchases of UK shares by directors that caught his eye over the past week and explains…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

35% of FTSE 100 firms use this award-winning US company to keep the wheels turning

This rapidly expanding software company helps one-third of FTSE 100 companies operate. I took a peak at its latest results…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Still under £4 despite strong recent results, is this FTSE retailer too big a bargain to pass up?

This FTSE stock looks set for strong earnings growth, which should drive its share price and dividend higher in my…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Here’s how I’d aim to turn £9,000 of abrdn shares into £1,960 a month in passive income!

abrdn shares deliver one of the highest yields in any FTSE index, enabling a relatively small amount to be turned…

Read more »

Investing Articles

10%+ yields! Here’s the dividend forecast for M&G shares to 2026

Only Phoenix Group offers a larger forward dividend yield than M&G shares. Does this make the FTSE 100 firm a…

Read more »